Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02874651
Other study ID # Ahead-N301
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 2016
Est. completion date August 27, 2020

Study information

Verified date December 2021
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will enroll patients with non-metastatic nasopharyngeal carcinoma (NPC) that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. The purpose is to evaluate the survival in these patients treated with apatinib (YN968D1), an inhibitor of vascular endothelial growth factor receptor (phase IIa) and to compare the survival in these patients treated with apatinib versus placebo (phase IIb).


Description:

This study has two parts. In the single arm phase IIa part, we will enroll 25 patients that have residual Epstein-Barr virus (EBV) DNA after curative radiotherapy or chemoradiotherapy. All patients will receive apatinib. The purpose is to evaluate the disease free-survival (DFS) in these patients treated with apatinib. In the phase IIb part, patients will be randomized to apatinib or placebo in a ratio of 1:1. The estimated sample size is 78 in phase IIb. However, the final sample size in phase IIb will be determined based on results of the phase IIa part.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date August 27, 2020
Est. primary completion date November 29, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Biopsy proven nasopharyngeal carcinoma, with detectable pretreatment plasma EBV DNA 2. Have detectable plasma EBV DNA at the end of (+/- 1 week) curative radiotherapy or chemoradiotherapy (radiation dose > 66Gy), determined by the central lab 3. No clinical evidence of persistent loco-regional disease 4. No evidence of distant metastasis, based upon skeletal scintigraphy, chest X-ray examination, and liver ultrasound or other appropriate workup (e.g., CT, MRI or positron emission tomography (PET)/CT]) within 21 days prior to registration 5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 6. Anticipated survival >= 3 months 7. Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 8. Platelets > 80,000 cells/mm^3 9. Hemoglobin >= 8.0 g/dl (no transfusion within the last 14 days) 10. Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) 11. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x institutional ULN 12. Creatinine clearance (CC) >= 50 ml/min estimated by Cockcroft-Gault formula Exclusion Criteria: 1. Patients with stage III-IV disease (American Joint Committee On Cancer/Union for International Cancer Control 7th) and no contraindication to chemotherapy that didn't receive platinum based concurrent chemotherapy during radiation 2. Patients with tumor possibly invaded main vessels (e.g. encasement of the internal jugular artery/vein) at diagnosis; or tumor that, in the judgment of the investigator, likely to invade main vessels and cause life-threatening hemorrhage events during study 3. History of serious hemorrhage events or grade 3 or higher hemorrhage within 4 weeks prior to registration 4. Hypertension that couldn't be well controlled with single medication; unstable angina; angina diagnosed within the last 3 months; myocardial infarction within the last 6 months; cardiac arrhythmia that need long-term medication; grade 2 or higher cardiac dysfunction (NYHA) 5. Proteinuria 6. Coagulation dysfunction or predisposition to hemorrhage; on treatment of anticoagulation medication or vitamin K antagonist; low dose warfarin (1mg po qd) or aspirin (less than 100mg daily) were permitted as long as the international normalized ratio (INR) = < 1.5 7. Thrombosis within the last 1 year, except cured vein thrombosis related to vein indwelling catheter 8. Unhealed bone fracture or chronic unhealed wound 9. Illness that would interfere with oral medication, including dysphagia, chronic diarrhea, or ileus 10. Pregnant or lactating women 11. Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception during and within 6 months after study 12. Current drug abuse or mentally disabled 13. History of congenital or acquired immune deficiency disease or organ transplantation 14. Major medical illness, which in the investigator's opinion would endanger the patients or interfere with the completion of therapy and follow up

Study Design


Intervention

Drug:
Apatinib
Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Placebo
Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.

Locations

Country Name City State
China Affiliated Foshan Hospital of Sun Yat-sen University Foshan Guangdong
China Sun Yat-sen University Cancer Center Guangzhou Guangdong
China Affiliated Hospital of Guilin Medical University Guilin Guangxi

Sponsors (3)

Lead Sponsor Collaborator
Sun Yat-sen University First People's Hospital of Foshan, Guilin Medical University, China

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival 3 years
Secondary overall survival 5 years
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 2 years
Secondary Changes in quality of life (QOL) as assessed by EORTC QLQ-C30 2 years
Secondary Distance Metastasis Free Survival 3 years
Secondary locoregional relapse free survival 3 years
Secondary Correlation of plasma EBV DNA load with the effect of apatinib on survival 3 years
Secondary Correlation of pretreatment serum VEGF level with the effect of apatinib on survival 3 years
Secondary Correlation of pretreatment serum VEGFR-2 level with the effect of apatinib on survival 3 years
Secondary Correlation of adverse event (hypertension) with the effect of apatinib on survival 3 years
Secondary Correlation of adverse event (hand-foot syndrome) with the effect of apatinib on survival 3 years
Secondary Correlation of the change from baseline in serum VEGF level at 4 weeks with the effect of apatinib on survival 3 years
Secondary Correlation of the change from baseline in serum VEGFR-2 level at 4 weeks with the effect of apatinib on survival 3 years
See also
  Status Clinical Trial Phase
Completed NCT01256853 - Modified Vaccinia Ankara (MVA) Vaccine Study Phase 1
Not yet recruiting NCT00577057 - Benefit of Changing Chemoradiotherapy Sequence and Modifying Radiotherapy Schedule for Advanced Nasopharyngeal Cancer N/A
Recruiting NCT02945878 - Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma N/A
Not yet recruiting NCT05807880 - Anlotinib, Penpulimab and Capecitabine in Recurrent/Metastatic Nasopharyngeal Carcinoma Phase 2
Completed NCT00342147 - Family Study of Head and Neck Cancers in Taiwan
Recruiting NCT02980315 - A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application Phase 1/Phase 2
Active, not recruiting NCT01735409 - Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma Phase 1/Phase 2
Completed NCT00565448 - Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents Phase 2
Completed NCT00630149 - Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Have Had Prior Platinum Based Chemotherapy Phase 2
Active, not recruiting NCT03854838 - IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Phase 2
Completed NCT01797900 - The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT Phase 2
Completed NCT00436800 - Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma Phase 2
Active, not recruiting NCT00563927 - Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0) N/A
Not yet recruiting NCT04870905 - Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma Phase 2
Active, not recruiting NCT02902432 - A Trial of Endostar in Patients With Carcinoma of the Head and Neck Phase 2
Active, not recruiting NCT02456506 - Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma. N/A
Completed NCT02444949 - A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Phase 2
Completed NCT00188877 - Intensity Modulated Radiation Therapy for Head and Neck Cancer Phase 2
Terminated NCT00393224 - Defining the Clinical Utility of EBV Antibody Screening to Identify Individuals Susceptible to Nasopharyngeal Carcinoma (NPC) Within High-Risk, Multiplex NPC Families
Not yet recruiting NCT03093649 - Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma N/A